HQL offers a 14.2% dividend yield and diverse exposure to healthcare and life science companies. Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price ...
HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to ...
PHILADELPHIA, PA / ACCESSWIRE / May 9, 2024 / abrdn Life Sciences Investors (HQL) and abrdn Healthcare Investors (HQH), (collectively, the "Funds") each, a closed-end management investment company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback